Stock Analysis
Marinomed Biotech (VIE:MARI) Third Quarter 2023 Results
Key Financial Results
- Revenue: €1.96m (down 11% from 3Q 2022).
- Net loss: €2.09m (loss widened by 7.3% from 3Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Marinomed Biotech Earnings Insights
Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Pharmaceuticals industry in Europe.
Performance of the market in Austria.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You should learn about the 3 warning signs we've spotted with Marinomed Biotech (including 1 which can't be ignored).
Valuation is complex, but we're helping make it simple.
Find out whether Marinomed Biotech is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WBAG:MARI
Marinomed Biotech
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally.
High growth potential and overvalued.
